Fernando I Yamauchi1, Tobias Penzkofer2, Andriy Fedorov3, Fiona M Fennessy4, Renxin Chu3, Stephan E Maier5, Clare M C Tempany3, Robert V Mulkern6, Lawrence P Panych7. 1. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Instituto de Radiologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil. 2. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany. 3. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. 5. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden. 6. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Radiology, Children's Hospital Boston, Harvard Medical School, Boston, MA. 7. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: panych@bwh.harvard.edu.
Abstract
OBJECTIVES: To evaluate the performance of T2 mapping in discriminating prostate cancer from normal prostate tissue in the peripheral zone using a practical reduced field-of-view MRI sequence requiring less than 3 minutes of scan time. MATERIALS AND METHODS: Thirty-six patients with biopsy-proven peripheral zone prostate cancer without prior treatment underwent routine multiparametric MRI at 3.0T with an endorectal coil. An Inner-Volume Carr-Purcell-Meiboom-Gill imaging sequence that required 2.8 minutes to obtain data for quantitative T2 mapping covering the entire prostate gland was added to the routine multiparametric protocol. Suspected cancer (SC) and suspected healthy (SH) tissue in the peripheral zone were identified in consensus by three radiologists and were correlated with available biopsy results. Differences in mean T2 values in SC and SH regions-of-interest (ROIs) were tested for significance using unpaired Student's two-tailed t-test. The area under the receiver operating characteristic curve was used to assess the optimal threshold T2 value for cancer discrimination. RESULTS: ROI analyses revealed significantly (p<0.0001) shorter T2 values in SC (85.4±12.3ms) compared to SH (169.6±38.7ms). An estimated T2 threshold of 99ms yielded a sensitivity of 92% and a specificity of 97% for prostate cancer discrimination. CONCLUSIONS: Quantitative values derived from this clinically practical T2-mapping sequence allow high precision discrimination between healthy and cancerous peripheral zone in the prostate.
OBJECTIVES: To evaluate the performance of T2 mapping in discriminating prostate cancer from normal prostate tissue in the peripheral zone using a practical reduced field-of-view MRI sequence requiring less than 3 minutes of scan time. MATERIALS AND METHODS: Thirty-six patients with biopsy-proven peripheral zone prostate cancer without prior treatment underwent routine multiparametric MRI at 3.0T with an endorectal coil. An Inner-Volume Carr-Purcell-Meiboom-Gill imaging sequence that required 2.8 minutes to obtain data for quantitative T2 mapping covering the entire prostate gland was added to the routine multiparametric protocol. Suspected cancer (SC) and suspected healthy (SH) tissue in the peripheral zone were identified in consensus by three radiologists and were correlated with available biopsy results. Differences in mean T2 values in SC and SH regions-of-interest (ROIs) were tested for significance using unpaired Student's two-tailed t-test. The area under the receiver operating characteristic curve was used to assess the optimal threshold T2 value for cancer discrimination. RESULTS: ROI analyses revealed significantly (p<0.0001) shorter T2 values in SC (85.4±12.3ms) compared to SH (169.6±38.7ms). An estimated T2 threshold of 99ms yielded a sensitivity of 92% and a specificity of 97% for prostate cancer discrimination. CONCLUSIONS: Quantitative values derived from this clinically practical T2-mapping sequence allow high precision discrimination between healthy and cancerous peripheral zone in the prostate.
Authors: Ian Chan; William Wells; Robert V Mulkern; Steven Haker; Jianqing Zhang; Kelly H Zou; Stephan E Maier; Clare M C Tempany Journal: Med Phys Date: 2003-09 Impact factor: 4.071
Authors: Agnieszka Szot Barnes; Steven J Haker; Robert V Mulkern; Minna So; Anthony V D'Amico; Clare M Tempany Journal: Urology Date: 2005-12 Impact factor: 2.649
Authors: G P Liney; A J Knowles; D J Manton; L W Turnbull; S J Blackband; A Horsman Journal: J Magn Reson Imaging Date: 1996 Jul-Aug Impact factor: 4.813
Authors: Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Marc R Engelbrecht; Henkjan J Huisman; Robert J F Laheij; Gerrit J Jager; Geert J L H van Leenders; Christina A Hulsbergen-Van De Kaa; Jean J M C H de la Rosette; Johan G Blickman; Jelle O Barentsz Journal: Radiology Date: 2003-08-27 Impact factor: 11.105
Authors: Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani Journal: Radiology Date: 2017-02-10 Impact factor: 11.105
Authors: Erik Velez; Andriy Fedorov; Kemal Tuncali; Olutayo Olubiyi; Christopher B Allard; Adam S Kibel; Clare M Tempany Journal: Abdom Radiol (NY) Date: 2017-08
Authors: Pelin Aksit Ciris; Jr-Yuan George Chiou; Daniel I Glazer; Tzu-Cheng Chao; Clare M Tempany-Afdhal; Bruno Madore; Stephan E Maier Journal: Invest Radiol Date: 2019-04 Impact factor: 6.016
Authors: Petra J van Houdt; Harsh K Agarwal; Laurens D van Buuren; Stijn W T P J Heijmink; Søren Haack; Henk G van der Poel; Ghazaleh Ghobadi; Floris J Pos; Johannes M Peeters; Peter L Choyke; Uulke A van der Heide Journal: Magn Reson Med Date: 2017-07-03 Impact factor: 4.668